Literature DB >> 21486280

Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment.

N A Fineberg1, S R Chamberlain, E Hollander, V Boulougouris, T W Robbins.   

Abstract

Obsessive-compulsive disorder (OCD) is characterized by obsessions (intrusive thoughts) and compulsions (repetitive ritualistic behaviours) leading to functional impairment. Accumulating evidence links these conditions with underlying dysregulation of fronto-striatal circuitry and monoamine systems. These abnormalities represent key targets for existing and novel treatment interventions. However, the brain bases of these conditions and treatment mechanisms are still not fully elucidated. Animal models simulating the behavioural and clinical manifestations of the disorder show great potential for augmenting our understanding of the pathophysiology and treatment of OCD. This paper provides an overview of what is known about OCD from several perspectives. We begin by describing the clinical features of OCD and the criteria used to assess the validity of animal models of symptomatology; namely, face validity (phenomenological similarity between inducing conditions and specific symptoms of the human phenomenon), predictive validity (similarity in response to treatment) and construct validity (similarity in underlying physiological or psychological mechanisms). We then survey animal models of OC spectrum conditions within this framework, focusing on (i) ethological models; (ii) genetic and pharmacological models; and (iii) neurobehavioural models. We also discuss their advantages and shortcomings in relation to their capacity to identify potentially efficacious new compounds. It is of interest that there has been rather little evidence of 'false alarms' for therapeutic drug effects in OCD models which actually fail in the clinic. While it is more difficult to model obsessive cognition than compulsive behaviour in experimental animals, it is feasible to infer cognitive inflexibility in certain animal paradigms. Finally, key future neurobiological and treatment research areas are highlighted.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2011        PMID: 21486280      PMCID: PMC3229751          DOI: 10.1111/j.1476-5381.2011.01422.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  187 in total

1.  Obsessive-compulsive spectrum phenomena and the DSM-V developmental process.

Authors:  Eric Hollander
Journal:  CNS Spectr       Date:  2008-02       Impact factor: 3.790

2.  The met(158) allele of catechol-O-methyltransferase (COMT) is associated with obsessive-compulsive disorder in men: case-control study and meta-analysis.

Authors:  E C Pooley; N Fineberg; P J Harrison
Journal:  Mol Psychiatry       Date:  2007-01-30       Impact factor: 15.992

3.  Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice.

Authors:  Jeffrey M Welch; Jing Lu; Ramona M Rodriguiz; Nicholas C Trotta; Joao Peca; Jin-Dong Ding; Catia Feliciano; Meng Chen; J Paige Adams; Jianhong Luo; Serena M Dudek; Richard J Weinberg; Nicole Calakos; William C Wetsel; Guoping Feng
Journal:  Nature       Date:  2007-08-23       Impact factor: 49.962

Review 4.  Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited.

Authors:  Lara Menzies; Samuel R Chamberlain; Angela R Laird; Sarah M Thelen; Barbara J Sahakian; Ed T Bullmore
Journal:  Neurosci Biobehav Rev       Date:  2007-10-17       Impact factor: 8.989

5.  The orbital cortex in rats topographically projects to central parts of the caudate-putamen complex.

Authors:  Eduardo A Schilman; Harry B M Uylings; Yvonne Galis-de Graaf; Daphna Joel; Henk J Groenewegen
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

6.  Evidence for a susceptibility locus on chromosome 10p15 in early-onset obsessive-compulsive disorder.

Authors:  Gregory L Hanna; Jeremy Veenstra-Vanderweele; Nancy J Cox; Michelle Van Etten; Daniel J Fischer; Joseph A Himle; Nancy Chiu Bivens; Xiaolin Wu; Cheryl A Roe; Kathleen A Hennessy; Diane E Dickel; Bennett L Leventhal; Edwin H Cook
Journal:  Biol Psychiatry       Date:  2007-06-04       Impact factor: 13.382

7.  Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat.

Authors:  Emma S J Robinson; Dawn M Eagle; Adam C Mar; Andrea Bari; Gargi Banerjee; Xiaosu Jiang; Jeffrey W Dalley; Trevor W Robbins
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

8.  Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.

Authors:  Samuel R Chamberlain; Natalia Del Campo; Jonathan Dowson; Ulrich Müller; Luke Clark; Trevor W Robbins; Barbara J Sahakian
Journal:  Biol Psychiatry       Date:  2007-07-17       Impact factor: 13.382

9.  Neurocognitive endophenotypes of obsessive-compulsive disorder.

Authors:  Lara Menzies; Sophie Achard; Samuel R Chamberlain; Naomi Fineberg; Chi-Hua Chen; Natalia del Campo; Barbara J Sahakian; Trevor W Robbins; Ed Bullmore
Journal:  Brain       Date:  2007-09-13       Impact factor: 13.501

Review 10.  Does obsessive-compulsive personality disorder belong within the obsessive-compulsive spectrum?

Authors:  Naomi A Fineberg; Punita Sharma; Thanusha Sivakumaran; Barbara Sahakian; Sam R Chamberlain; Sam Chamberlain
Journal:  CNS Spectr       Date:  2007-06       Impact factor: 3.790

View more
  26 in total

Review 1.  From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?

Authors:  A Richard Green; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

Authors:  Silvia Victoria Navarro; Valeria Gutiérrez-Ferre; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2014-08-26       Impact factor: 4.530

3.  Translational neuropharmacology and the appropriate and effective use of animal models.

Authors:  A R Green; J Gabrielsson; K C F Fone
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 4.  Transcranial cortical stimulation in the treatment of obsessive-compulsive disorders: efficacy studies.

Authors:  Ghassen Saba; Albert Moukheiber; Antoine Pelissolo
Journal:  Curr Psychiatry Rep       Date:  2015-05       Impact factor: 5.285

Review 5.  A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Simone Rehn; Guy D Eslick; Vlasios Brakoulias
Journal:  Psychiatr Q       Date:  2018-09

Review 6.  Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases.

Authors:  Margarita Moreno; Pilar Flores
Journal:  Psychopharmacology (Berl)       Date:  2011-11-24       Impact factor: 4.530

7.  Neurocognitive Endophenotypes of OCD.

Authors:  Matilde M Vaghi
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 8.  Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.

Authors:  De Wet Wolmarans; Isabella M Scheepers; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-12-06       Impact factor: 3.584

9.  Medial Orbitofrontal Cortex Regulates Instrumental Conditioned Punishment, but not Pavlovian Conditioned Fear.

Authors:  Cassandra Ma; Philip Jean-Richard-Dit-Bressel; Stephanie Roughley; Bryce Vissel; Bernard W Balleine; Simon Killcross; Laura A Bradfield
Journal:  Cereb Cortex Commun       Date:  2020-07-30

10.  From impulses to maladaptive actions: the insula is a neurobiological gate for the development of compulsive behavior.

Authors:  A Belin-Rauscent; M-L Daniel; M Puaud; B Jupp; S Sawiak; D Howett; C McKenzie; D Caprioli; M Besson; T W Robbins; B J Everitt; J W Dalley; D Belin
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.